Publication

Clinical Validation of a QSP Model for ISB 2001, a Trispecific T Cell Engager to Support Optimal FIH Study Design in RRMM Patients

See how a QSP model guided efficacy-proximal FIH dosing for ISB 2001 in the TRIgnite-1…

CertaraJune 4, 2026

Video

Applying AI-Driven Biosimulation to Drug Discovery

Certara President Leif Pedersen explains how PBPK and QSP modeling, proven across 125+ FDA-approved drugs,…

CertaraJune 2, 2026

Case Study

Model-Informed Development Accelerates Transformative Treatment for Sleeping Sickness

Certara’s drug development support enabled a positive scientific opinion from the EMA for acoziborole, a…

CertaraJune 2, 2026

Blog

Strategies for navigating loss of exclusivity (LOE) in pharma

Learn key strategies to navigate loss of exclusivity with confidence & defend market share throughout…

CertaraJune 2, 2026

Publication

Review: application and opportunities for machine learning and artificial intelligence in preclinical immunogenicity risk assessment

This review explores how artificial intelligence (AI), machine learning (ML), and quantitative systems pharmacology (QSP)…

CertaraJune 2, 2026

Webinar

Model Acceptance in Regulatory Submissions: Practical Strategies for Regulatory Success

CertaraJune 1, 2026

Blog

How to Choose the Right LLM for Medical Writing

What makes great GenAI medical writing software? See how medical writing artificial intelligence and model…

CertaraMay 28, 2026

Fact Sheet

Certara’s NLME Engine: Setting the Standard for Run Speed and Stability

Why pharmacometricians are turning to the NLME engine from Certara Phoenix

CertaraMay 28, 2026

Publication

Oxford Academic, Neuro-Oncology Pediatrics – BRAF pub: Growth recovery in patients with BRAF-altered pediatric low-grade glioma following treatment with tovorafenib

This publication reports a pooled retrospective analysis evaluating growth patterns in children with B-Raf proto-oncogene…

Dorottya Gui-BodnarMay 28, 2026

On-Demand Webinar

The Modeling Advantage: How Forward-Thinking Sponsors Are Moving Faster, De-Risking Earlier, and Winning with Regulators

Learn how PBPK and QSP modeling support regulatory confidence, accelerate drug development, and align with…

CertaraMay 26, 2026

Clinical Validation of a QSP Model for ISB 2001, a Trispecific T Cell Engager to Support Optimal FIH Study Design in RRMM Patients

Applying AI-Driven Biosimulation to Drug Discovery

Model-Informed Development Accelerates Transformative Treatment for Sleeping Sickness

Strategies for navigating loss of exclusivity (LOE) in pharma

Review: application and opportunities for machine learning and artificial intelligence in preclinical immunogenicity risk assessment

Model Acceptance in Regulatory Submissions: Practical Strategies for Regulatory Success

How to Choose the Right LLM for Medical Writing

Certara’s NLME Engine: Setting the Standard for Run Speed and Stability

Oxford Academic, Neuro-Oncology Pediatrics – BRAF pub: Growth recovery in patients with BRAF-altered pediatric low-grade glioma following treatment with tovorafenib

The Modeling Advantage: How Forward-Thinking Sponsors Are Moving Faster, De-Risking Earlier, and Winning with Regulators

Newsletter sign up

Quick links

Solutions

Contact